Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray against Common Cold

VIENNA--(BUSINESS WIRE)-- Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia. This nasal spray is based on Marinomed’s anti-viral respiratory technology platform mavirex. Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties. Further financial details were not disclosed.

Respiratory viruses are responsible for the most common infectious disease in humans – the common cold. Boehringer Ingelheim plans to market the anti-viral nasal spray under the well-known cough and cold brand Mucosolvan®.

“mavirex” is Marinomed’s proprietary anti-viral respiratory technology platform to develop therapies that target more than 200 different respiratory virus strains and Marinomed is investigating the technology for use in a range of other products. The use of the mavirex technology platform for treatment of influenza and in combination products is not included in the agreement.

Dr. Thomas Friedrich, CFO of Marinomed, said:

“This is a landmark agreement for Marinomed. We are delighted to commence a long-term collaboration with Boehringer Ingelheim, a perfect partner for the successful marketing of our innovative common cold product worldwide.”

Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented:

“We are very excited to have signed this deal with Boehringer Ingelheim. Our anti-viral respiratory technology platform has already been validated in clinical trials with adults and children, demonstrating efficacy as an antiviral treatment in treating the cause of the common cold.”

“This licensing agreement is an excellent strategic fit with our ongoing development of new and innovative products designed to afford consumers a range of Over-the-Counter medicines to treat the common cold and related diseases, as well as their associated symptoms.” explained David Wright, Boehringer Ingelheim’s Corporate Senior Vice President Consumer Healthcare.

Marinomed used Proksch & Fritzsche (Vienna) for legal advice and worked together with the business development consultants from Bionest Partners (Paris).

About Marinomed Biotechnologie GmbH

Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative anti-viral respiratory technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed´s additional products concentrating on influenza, combination products for asthmatics and other high-risk patients. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria. For further information please visit the website at www.marinomed.com

Boehringer Ingelheim GmbH

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com



CONTACT:

Marinomed Biotechnologie GmbH
Johanna Uhlmann
Business Development
Tel: +43 (0)1 25077 4460
[email protected]
or
College Hill
Dr. Douglas Pretsell
Associate Partner
Tel : +49 (0) 89 5700 1806
[email protected]

KEYWORDS:   Austria  Europe  France  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.